Skip to content

Study · Non-randomized trial · 2023

11 results

Sexual and Reproductive Outcomes in Obese Fertile Men with Functional Hypogonadism after Treatment with Liraglutide: Preliminary Results.

La Vignera S, Condorelli RA, Calogero AE, Cannarella R, Aversa A

Journal of clinical medicine14 Jan 2023Cited by 50 (Europe PMC)

PMID36675601 (opens in a new tab)PMCIDPMC9860933 (opens in a new tab)DOI10.3390/jcm12020672 (opens in a new tab)PepBankPUB-36675601
Download PDFPubMedAsk about this study
Jump to 11 results

Summary

Purpose: To prospectively investigate the effects of treatment with liraglutide, a glucagon-like peptide 1 (GLP1) analog, on reproductive and sexual function in men with metabolic hypogonadism who are of childbearing age. Materials and Methods: To accomplish this purpose, 110 men of childbearing age (18-35 years) with metabolic hypogonadism were enrolled and divided into three groups, according to their desire to have children. Group A was made up of men actively seeking fatherhood, Group B, of men who did not seek fatherhood, and Group C, of men who had already fathered a child. Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day). All patients were treated for 4 months. Results: Patients treated with liraglutide (Group B) showed significant improvement in conventional sperm parameters, compared to baseline and Group A patients, and in the quality of erectile function compared to baseline and patients of Groups A and C. In addition, they had significantly higher levels of total testosterone and sex hormone-binding globulin serum levels after 4 months of treatment with liraglutide than those achieved by patients in the other two groups at the end of the respective treatments. Finally, Group B patients also showed significantly higher serum gonadotropin levels than the other groups. Conclusions: The results of this study showed, for the first time, the efficacy of liraglutide, a GLP1 analog, for the pharmacological treatment of male patients with metabolic hypogonadism. Liraglutide has also shown advantages over traditional treatments on both reproductive and sexual function and appears to offer greater benefits in terms of metabolic protection. These findings suggest that liraglutide is a useful drug for the treatment of obese males with metabolic hypogonadism.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In men with metabolic hypogonadism, liraglutide improved conventional sperm parameters compared with baseline.

    In plain wordsIn men with metabolic hypogonadism, liraglutide improved sperm measures compared with baseline.

    Peptide
    Liraglutide
    Outcome
    IncreaseConventional sperm parameters versus baseline
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mg daily · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients treated with liraglutide (Group B) showed significant improvement in conventional sperm parameters, compared to baseline and Group A patients, and in the quality of erectile function compared to baseline and patients of Groups A and C.
    4 context sentences
    Summary · context
    To accomplish this purpose, 110 men of childbearing age (18-35 years) with metabolic hypogonadism were enrolled and divided into three groups, according to their desire to have children.
    Summary · context
    Group A was made up of men actively seeking fatherhood, Group B, of men who did not seek fatherhood, and Group C, of men who had already fathered a child.
    Summary · context
    Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day).
    Summary · context
    All patients were treated for 4 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In men with metabolic hypogonadism, liraglutide improved conventional sperm parameters compared with gonadotropin treatment.

    In plain wordsIn men with metabolic hypogonadism, liraglutide improved sperm measures compared with urofollitropin and hCG.

    Peptide
    Liraglutide
    Outcome
    IncreaseConventional sperm parameters versus gonadotropins
    Study

    n: not reported in source

    Comparator
    Urofollitropin and hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mg daily · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients treated with liraglutide (Group B) showed significant improvement in conventional sperm parameters, compared to baseline and Group A patients, and in the quality of erectile function compared to baseline and patients of Groups A and C.
    4 context sentences
    Summary · context
    To accomplish this purpose, 110 men of childbearing age (18-35 years) with metabolic hypogonadism were enrolled and divided into three groups, according to their desire to have children.
    Summary · context
    Group A was made up of men actively seeking fatherhood, Group B, of men who did not seek fatherhood, and Group C, of men who had already fathered a child.
    Summary · context
    Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day).
    Summary · context
    All patients were treated for 4 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In men with metabolic hypogonadism, liraglutide improved erectile function compared with baseline.

    In plain wordsIn men with metabolic hypogonadism, liraglutide improved erectile function compared with baseline.

    Peptide
    Liraglutide
    Outcome
    IncreaseErectile function versus baseline
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    3 mg daily · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients treated with liraglutide (Group B) showed significant improvement in conventional sperm parameters, compared to baseline and Group A patients, and in the quality of erectile function compared to baseline and patients of Groups A and C.
    4 context sentences
    Summary · context
    To accomplish this purpose, 110 men of childbearing age (18-35 years) with metabolic hypogonadism were enrolled and divided into three groups, according to their desire to have children.
    Summary · context
    Group A was made up of men actively seeking fatherhood, Group B, of men who did not seek fatherhood, and Group C, of men who had already fathered a child.
    Summary · context
    Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day).
    Summary · context
    All patients were treated for 4 months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In men with metabolic hypogonadism, liraglutide improved erectile function compared with gonadotropin treatment.

    In plain wordsIn men with metabolic hypogonadism, liraglutide improved erectile function compared with urofollitropin and hCG.

    Peptide
    Liraglutide
    Outcome
    IncreaseErectile function versus gonadotropins
    Study

    n: not reported in source

    Comparator
    Urofollitropin and hCG
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    3 mg daily · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients treated with liraglutide (Group B) showed significant improvement in conventional sperm parameters, compared to baseline and Group A patients, and in the quality of erectile function compared to baseline and patients of Groups A and C.
    4 context sentences
    Summary · context
    To accomplish this purpose, 110 men of childbearing age (18-35 years) with metabolic hypogonadism were enrolled and divided into three groups, according to their desire to have children.
    Summary · context
    Group A was made up of men actively seeking fatherhood, Group B, of men who did not seek fatherhood, and Group C, of men who had already fathered a child.
    Summary · context
    Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day).
    Summary · context
    All patients were treated for 4 months.
  5. 05HumanNon-randomized trialEfficacy outcome

    In men with metabolic hypogonadism, liraglutide improved erectile function compared with transdermal testosterone.

    In plain wordsIn men with metabolic hypogonadism, liraglutide improved erectile function compared with transdermal testosterone.

    Peptide
    Liraglutide
    Outcome
    IncreaseErectile function versus testosterone
    Study

    n: not reported in source

    Comparator
    Transdermal testosterone
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    3 mg daily · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients treated with liraglutide (Group B) showed significant improvement in conventional sperm parameters, compared to baseline and Group A patients, and in the quality of erectile function compared to baseline and patients of Groups A and C.
    4 context sentences
    Summary · context
    To accomplish this purpose, 110 men of childbearing age (18-35 years) with metabolic hypogonadism were enrolled and divided into three groups, according to their desire to have children.
    Summary · context
    Group A was made up of men actively seeking fatherhood, Group B, of men who did not seek fatherhood, and Group C, of men who had already fathered a child.
    Summary · context
    Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day).
    Summary · context
    All patients were treated for 4 months.
  6. 06HumanNon-randomized trialEfficacy outcome

    In men with metabolic hypogonadism, liraglutide produced higher total testosterone levels than gonadotropin treatment.

    In plain wordsIn men with metabolic hypogonadism, liraglutide produced higher total testosterone than urofollitropin and hCG.

    Peptide
    Liraglutide
    Outcome
    IncreaseTotal testosterone versus gonadotropins
    Study

    n: not reported in source

    Comparator
    Urofollitropin and hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mg daily · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    In addition, they had significantly higher levels of total testosterone and sex hormone-binding globulin serum levels after 4 months of treatment with liraglutide than those achieved by patients in the other two groups at the end of the respective treatments.
    4 context sentences
    Summary · context
    To accomplish this purpose, 110 men of childbearing age (18-35 years) with metabolic hypogonadism were enrolled and divided into three groups, according to their desire to have children.
    Summary · context
    Group A was made up of men actively seeking fatherhood, Group B, of men who did not seek fatherhood, and Group C, of men who had already fathered a child.
    Summary · context
    Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day).
    Summary · context
    All patients were treated for 4 months.
  7. 07HumanNon-randomized trialEfficacy outcome

    In men with metabolic hypogonadism, liraglutide produced higher total testosterone levels than transdermal testosterone.

    In plain wordsIn men with metabolic hypogonadism, liraglutide produced higher total testosterone than transdermal testosterone treatment.

    Peptide
    Liraglutide
    Outcome
    IncreaseTotal testosterone versus testosterone therapy
    Study

    n: not reported in source

    Comparator
    Transdermal testosterone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mg daily · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    In addition, they had significantly higher levels of total testosterone and sex hormone-binding globulin serum levels after 4 months of treatment with liraglutide than those achieved by patients in the other two groups at the end of the respective treatments.
    4 context sentences
    Summary · context
    To accomplish this purpose, 110 men of childbearing age (18-35 years) with metabolic hypogonadism were enrolled and divided into three groups, according to their desire to have children.
    Summary · context
    Group A was made up of men actively seeking fatherhood, Group B, of men who did not seek fatherhood, and Group C, of men who had already fathered a child.
    Summary · context
    Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day).
    Summary · context
    All patients were treated for 4 months.
  8. 08HumanNon-randomized trialEfficacy outcome

    In men with metabolic hypogonadism, liraglutide produced higher sex hormone-binding globulin levels than gonadotropin treatment.

    In plain wordsIn men with metabolic hypogonadism, liraglutide produced higher sex hormone-binding globulin than urofollitropin and hCG.

    Peptide
    Liraglutide
    Outcome
    IncreaseSex hormone-binding globulin versus gonadotropins
    Study

    n: not reported in source

    Comparator
    Urofollitropin and hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mg daily · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    In addition, they had significantly higher levels of total testosterone and sex hormone-binding globulin serum levels after 4 months of treatment with liraglutide than those achieved by patients in the other two groups at the end of the respective treatments.
    4 context sentences
    Summary · context
    To accomplish this purpose, 110 men of childbearing age (18-35 years) with metabolic hypogonadism were enrolled and divided into three groups, according to their desire to have children.
    Summary · context
    Group A was made up of men actively seeking fatherhood, Group B, of men who did not seek fatherhood, and Group C, of men who had already fathered a child.
    Summary · context
    Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day).
    Summary · context
    All patients were treated for 4 months.
  9. 09HumanNon-randomized trialEfficacy outcome

    In men with metabolic hypogonadism, liraglutide produced higher sex hormone-binding globulin levels than transdermal testosterone.

    In plain wordsIn men with metabolic hypogonadism, liraglutide produced higher sex hormone-binding globulin than transdermal testosterone.

    Peptide
    Liraglutide
    Outcome
    IncreaseSex hormone-binding globulin versus testosterone
    Study

    n: not reported in source

    Comparator
    Transdermal testosterone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mg daily · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    In addition, they had significantly higher levels of total testosterone and sex hormone-binding globulin serum levels after 4 months of treatment with liraglutide than those achieved by patients in the other two groups at the end of the respective treatments.
    4 context sentences
    Summary · context
    To accomplish this purpose, 110 men of childbearing age (18-35 years) with metabolic hypogonadism were enrolled and divided into three groups, according to their desire to have children.
    Summary · context
    Group A was made up of men actively seeking fatherhood, Group B, of men who did not seek fatherhood, and Group C, of men who had already fathered a child.
    Summary · context
    Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day).
    Summary · context
    All patients were treated for 4 months.
  10. 10HumanNon-randomized trialEfficacy outcome

    In men with metabolic hypogonadism, liraglutide produced higher serum gonadotropin levels than gonadotropin treatment.

    In plain wordsIn men with metabolic hypogonadism, liraglutide produced higher blood gonadotropins than urofollitropin and hCG.

    Peptide
    Liraglutide
    Outcome
    IncreaseSerum gonadotropins versus gonadotropin treatment
    Study

    n: not reported in source

    Comparator
    Urofollitropin and hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mg daily · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Finally, Group B patients also showed significantly higher serum gonadotropin levels than the other groups.
    4 context sentences
    Summary · context
    To accomplish this purpose, 110 men of childbearing age (18-35 years) with metabolic hypogonadism were enrolled and divided into three groups, according to their desire to have children.
    Summary · context
    Group A was made up of men actively seeking fatherhood, Group B, of men who did not seek fatherhood, and Group C, of men who had already fathered a child.
    Summary · context
    Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day).
    Summary · context
    All patients were treated for 4 months.
  11. 11HumanNon-randomized trialEfficacy outcome

    In men with metabolic hypogonadism, liraglutide produced higher serum gonadotropin levels than transdermal testosterone.

    In plain wordsIn men with metabolic hypogonadism, liraglutide produced higher blood gonadotropins than transdermal testosterone.

    Peptide
    Liraglutide
    Outcome
    IncreaseSerum gonadotropins versus testosterone
    Study

    n: not reported in source

    Comparator
    Transdermal testosterone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mg daily · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Finally, Group B patients also showed significantly higher serum gonadotropin levels than the other groups.
    4 context sentences
    Summary · context
    To accomplish this purpose, 110 men of childbearing age (18-35 years) with metabolic hypogonadism were enrolled and divided into three groups, according to their desire to have children.
    Summary · context
    Group A was made up of men actively seeking fatherhood, Group B, of men who did not seek fatherhood, and Group C, of men who had already fathered a child.
    Summary · context
    Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day).
    Summary · context
    All patients were treated for 4 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 2

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.